Drug intelligence / Profile preview

reRNA HPV tumor vaccine

Development stage: Preclinical
Lead developer: Jiangsu Leeway Biological Technology
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

reRNA HPV tumor vaccine is an RNA-based therapeutic vaccine designed to treat human papillomavirus (HPV)-related cancers. It functions by delivering RNA instructions to cells, enabling them to produce HPV antigens, primarily the E6 and E7 oncoproteins. This process stimulates the patient's immune system, specifically activating CD8+ T cells, to recognize and destroy HPV-infected tumor cells. The vaccine is being developed by Jiangsu Leeway Biological Technology Co., Ltd. for HPV16/18-positive unresectable recurrent or metastatic solid tumors.

Brand names: reRNA-HPV肿瘤疫苗
Other names: reRNA-HPV肿瘤疫苗

Targets

E7 (Papillomavirus E6/E7 oncoproteins)E6/E7 (HPV E6/E7 oncoproteins)

Beyond the preview

Go deeper on reRNA HPV tumor vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on reRNA HPV tumor vaccine.

Explore the full profile